Editor's Note: the "Trending USA Stocks" column tracks the day's top bullish stocks in the USA market, aiding investors in promptly identifying opportunities for potential gains.

23/07/2025 Eastern Time in USA The Dow Jones Industrial Average rose by 1.14%, closing at 45010.29 points; the Nasdaq Composite rose by 0.61%, closing at 21020.02 points; the S&P 500 Index rose by 0.78%, closing at 6358.91 points. Sahm has compiled the Top 10 Daily Stock Price Gainers in the USA market.

Abivax S.A.: Overnight gain 586.0%, Positive clinical trial results for ulcerative colitis drug boost investor confidence and stock price.

Abivax S.A., a French clinical-stage biotechnology firm founded in 2013, is at the forefront of developing innovative therapies that harness the body's natural regulatory mechanisms to modulate immune responses in patients with chronic inflammatory diseases. The company's lead candidate, obefazimod, is currently advancing through Phase 3 clinical trials for the treatment of moderate to severe active ulcerative colitis in adults. Abivax's strategic focus lies in leveraging cutting-edge science to address unmet medical needs in the inflammatory disease space. By targeting novel pathways, the company aims to deliver transformative therapies that could potentially improve the quality of life for patients suffering from these debilitating conditions. The progression of obefazimod to late-stage clinical development underscores Abivax's commitment to driving innovation in the therapeutic landscape for inflammatory disorders. As the company continues to advance its pipeline, investors and industry observers will be closely monitoring the outcomes of these pivotal trials, which could have significant implications for both patients and the broader biotech sector.

Abivax S.A.(ABVX.US) shares soared on Wednesday following the announcement of positive Phase 3 clinical trial results for its lead drug candidate, obefazimod, in treating moderate to severe active ulcerative colitis. The trial met the FDA's primary endpoint, demonstrating significant clinical remission at the 50mg once-daily dose. The drug's safety profile was confirmed, with no new safety signals observed. Abivax plans to submit a New Drug Application to regulatory authorities in 2026. Several investment firms raised their price targets for ABVX, reflecting optimistic market sentiment towards the company's prospects. These factors collectively drove ABVX's stock price up by 586.0% in a single day, bringing its year-to-date gain to an impressive 837.2%.

Rich Sparkle Holdings Ltd. Ordinary Shares: Overnight gain 59.2%, New listing attracts investors with financial printing expertise and market optimism.

Rich Sparkle Holdings Ltd., a financial printing and corporate services provider, was incorporated in the British Virgin Islands on January 2, 2024. The company specializes in delivering high-quality financial printing materials to the Hong Kong market, with a service portfolio encompassing listing documents, financial reports, fund documents, circulars, and announcements. The firm offers comprehensive financial printing solutions to its clientele, covering various aspects of the process including typesetting, proofreading, translation, design, and printing. These services are tailored to meet the sophisticated demands of the financial industry. Rich Sparkle Holdings Ltd. aims to establish itself as a key player in Hong Kong's financial printing sector, leveraging its expertise to support clients in meeting regulatory requirements and enhancing their corporate communications. The company's strategic focus on the Hong Kong market positions it to capitalize on the region's dynamic financial landscape and growing demand for professional printing services.

Rich Sparkle Holdings Ltd. Ordinary Shares(ANPA.US) has experienced a notable surge in stock price, driven by multiple factors. As a newly listed entity, the company's specialized expertise in financial printing and corporate services has garnered significant investor attention. Rich Sparkle Holdings (ANPA) offers comprehensive services from typesetting to printing, catering to the high-quality printing material demands of Hong Kong's financial market. Recent market vibrancy has fueled the company's business growth, coupled with investors' optimistic outlook on its future prospects. This combination has propelled the stock price upward. ANPA has achieved a remarkable 59.2% increase in the short term, with a cumulative rise of 378.0% year-to-date, reflecting the market's positive expectations for the company's future growth potential in the financial printing sector.

Safety Shot, Inc. - Common Stock: Overnight gain 29.8%, Compliance extension, successful fundraising, merger approval, and innovative product drive bullish sentiment.

Safety Shot, Inc. (NASDAQ: SHOT), a Delaware-incorporated company established on October 24, 2018, is emerging as a key player in the health and functional beverage sector. The firm is currently in the development phase of its flagship product, Safety Shot, an innovative functional beverage leveraging proprietary technology. The company's groundbreaking formulation is designed to expedite the reduction of blood alcohol concentration while simultaneously enhancing cognitive alertness, effectively accelerating the return to sobriety. This unique value proposition positions Safety Shot as a potential game-changer in the rapidly expanding functional beverage market. Safety Shot's product aims to address a significant consumer need by offering a quick and efficient solution to mitigate the effects of alcohol consumption. As the functional beverage industry continues to evolve, Safety Shot, Inc. is poised to capitalize on the growing demand for health-conscious and practical drinking alternatives. Investors and industry observers are closely monitoring the company's progress as it navigates the final stages of product development and prepares for market entry. The success of Safety Shot could potentially disrupt the beverage landscape and create new opportunities in the intersection of health, wellness, and social drinking.

The recent surge in Safety Shot, Inc. - Common Stock(SHOT.US) can be attributed to several key factors. Notably, the company secured a 180-day compliance extension from Nasdaq, averting potential delisting concerns. Additionally, Safety Shot successfully completed two funding rounds, raising approximately $10.6 million and $16.3 million respectively, significantly bolstering its financial position. Furthermore, shareholders approved the merger with Yerbaé, injecting new momentum into the company's future prospects. The innovative product Sure Shot, developed by Safety Shot as the first patented supplement designed to reduce blood alcohol content, has already launched on multiple platforms, demonstrating promising market potential. These positive developments collectively propelled SHOT's stock price, resulting in a substantial single-day gain of 29.8% and a year-to-date increase of 33.1%.

The Top 10 Daily Gainers in the USA market are listed as follows:

Editor's note: This content was generated by Sahm's in-house AI-enabled SaaS tool and was reviewed by our editing team.